REG - Accrol Group Hldgs - Appointment of Joint Broker

Accrol groupAnnouncement

17/03/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200317:nRSQ3149Ga

RNS Number : 3149G  Accrol Group Holdings PLC  17 March 2020

17 March 2020

 

Accrol Group Holdings plc

(AIM: ACRL)

 

Appointment of Joint Broker

 

Accrol Group Holdings plc (the "Company" or "Accrol"), the UK's leading
independent tissue converter, is pleased to announce the appointment of
Liberum Capital Limited as joint broker to the Company with immediate effect.

 

 For further information, please contact:

 Accrol Group Holdings plc
 Dan Wright, Executive Chairman                           Tel: +44 (0) 1254 278 844
 Gareth Jenkins, Chief Executive Officer

 Zeus Capital Limited (Nominated Adviser & Broker)
 Dan Bate / Andrew Jones                                  Tel: +44 (0) 161 831 1512
 Dominic King / John Goold                                Tel: +44 (0) 203 829 5000

 Liberum Capital Limited (Joint Broker)
 Clayton Bush / Edward Thomas                             Tel: +44 (0) 20 3100 2000

 Belvedere Communications Limited
 Cat Valentine                                            Tel: +44 (0) 7715 769 078
 Keeley Clarke                                            Tel: +44 (0) 7967 816 525
 Llew Angus                                               Tel: +44 (0) 7407 023 147
                                                          AccrolPR@BelvederePR.com (mailto:AccrolPR@BelvederePR.com)

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter
and supplier of toilet rolls, kitchen rolls and facial tissues, as well as
other tissue products, to major discounters and grocery retailers throughout
the UK.

 

The business operates from four sites in Lancashire:

 

·      A manufacturing, storage and distribution facility in Blackburn;

·      A storage and administrative centre in Blackburn;

·      A facial tissue plant, also in Blackburn; and

·      A manufacturing, storage and distribution facility in Leyland.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  APPBSGDXRBBDGGL